Payment overview · 2025
General Payments
$347.60
13 reported records · 6 companies
Healthcare provider profile · identity verified
Alan Jay Sherman, MD
Allopathic & Osteopathic Physicians|General Practice · MOBILE, AL · NPI 1952315343
Verified facts
What the public records show
CMS Open Payments records show Alan Jay Sherman, MD received $347.60 in general payments during 2025 across 13 reported records.
Gilead Sciences, Inc. accounted for 47.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $165.41 | 47.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.29 | 17.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.01 | 15.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.32 | 8.4% | 1 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $19.25 | 5.5% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.32 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $347.60 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $135.07 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $61.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 243 |
| Amlodipine Besylate | Amlodipine Besylate | 666 | 192 |
| Lisinopril | Lisinopril | 394 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 99 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 84 |
| Losartan Potassium | Losartan Potassium | 269 | 85 |
| Omeprazole | Omeprazole | 229 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 65 |
| Ezetimibe | Ezetimibe | 213 | 72 |
| Meloxicam | Meloxicam | 201 | 63 |
| Metformin Hcl | Metformin Hcl | 200 | 61 |
| Metformin Hcl Er | Metformin Hcl | 199 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 192 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 52 |
| Famotidine | Famotidine | 161 | 47 |
| Gabapentin | Gabapentin | 157 | 30 |
| Montelukast Sodium | Montelukast Sodium | 153 | 48 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 151 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 149 | 43 |
| Furosemide | Furosemide | 148 | 47 |
| Potassium Chloride | Potassium Chloride | 144 | 41 |
| Carvedilol | Carvedilol | 140 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 48 |
| Tramadol Hcl | Tramadol Hcl | 129 | 33 |
| Trazodone Hcl | Trazodone Hcl | 122 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 32 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 117 | 34 |
| Glimepiride | Glimepiride | 116 | 37 |
| Terazosin Hcl | Terazosin Hcl | 114 | 36 |
| Simvastatin | Simvastatin | 109 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 34 |
| Ozempic | Semaglutide | 91 | 18 |
| Alendronate Sodium | Alendronate Sodium | 87 | 26 |
| Fenofibrate | Fenofibrate | 85 | 24 |
| Celecoxib | Celecoxib | 82 | 20 |
| Allopurinol | Allopurinol | 75 | 24 |
| Farxiga | Dapagliflozin Propanediol | 74 | 19 |
| Finasteride | Finasteride | 72 | 24 |
| Eliquis | Apixaban | 71 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 29 |
| Ketoconazole | Ketoconazole | 62 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 12 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 16 |
| Atenolol | Atenolol | 39 | 15 |
| Ibuprofen | Ibuprofen | 39 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | 16 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 14 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Baclofen | Baclofen | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 12 |
| Methylprednisolone | Methylprednisolone | 28 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 16 |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Prednisone | Prednisone | 26 | 23 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 14 |
| Torsemide | Torsemide | 23 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Digoxin | Digoxin | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $347.60 · 13 records | Gilead Sciences, Inc. | AIRSUPRA, Auvelity, BREZTRI, Epclusa, FARXIGA, FEMLYV, INTRAROSA, MAVYRET, Natroba, Spinosad | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error